← Eichor
Study identifier: NCT06507683 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

Condition: Gastrointestinal Stromal Tumors  ·  Sponsor: First Affiliated Hospital of Chongqing Medical University

PhaseNA
Planned participants32
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?

This description comes directly from the study's public registry record.

Talk to the study team

Jun Zhang, MD  ·  +86 136 1766 6067  ·  zjun2323@sina.cn

Longhao Li, MD  ·  +86 183 7580 7001  ·  llh@hospital.cqmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Chongqing Medical UniversityChongqing, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06507683